A randomized phase II trial of adjuvant chemotherapy with cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG regimen) or gemcitabine alone after curative resection for pancreatic cancer

4608 Background: The PEFG regimen yielded a statistically relevant outcome advantage as compared with gemcitabine (G) in patients with advanced pancreatic adenocarcinoma (PA). The current trial assessed the impact upon disease control of PEFG regimen and single agent G after curative resection for PA. At time of trial design, both arms were experimental since the role of adjuvant therapy in PA was debated. Methods: After R0 or R1 resection for...